Jan. 9 -- GlaxoSmithKline and XenoPort, Inc. announced today that GSK has resubmitted the New Drug Application to the U.S. FDA requesting approval of Solzira (gabapentin enacarbil) Extended Release Tablets for the treatment of moderate-to-severe
The details can be read here.
No comments:
Post a Comment